Stocks · News reference
Filed: 2026-08-05 AccNo: 0001104659-26-091269 Size: 595 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Submission supported by data from Phase 3 pivotal AFFIRM studyIf approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV)
Read original at benzingaBillionaire hedge fund manager Ken Griffin's Citadel increased its stake in AbbVie by 547% in Q2, adding 2.7 million shares worth approximately $798 million. The move reflects a defensive investment strategy into a stable dividend stock. AbbVie, a Dividend King with 54 consecutive years of dividend increases, currently yields 2.6% and has 75% of Wall Street analysts rating it as a buy with a median price target of $282.50.
Read original at the-motley-foolBillionaire hedge fund manager Ken Griffin recently increased his stakes in AbbVie and Abbott Laboratories through his fund Citadel. The article analyzes whether retail investors should follow his lead, highlighting AbbVie's transition from Humira to new immunology drugs like Skyrizi and Rinvoq with expansion into oncology, and Abbott's strong positions in diabetes care, diagnostics, and medical devices. The author suggests both stocks merit consideration as part of a long-term healthcare allocation based on their business fundamentals rather than simply following Griffin's moves.
Read original at the-motley-foolAbbVie (NYSE:ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer
Read original at benzinga